NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Immunocore Ltd
Replimune Inc.
BioInvent International AB
TriSalus Life Sciences, Inc.
Viralytics
Bristol-Myers Squibb